Masofaniten
A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended.
ESSA Pharma terminated the phase 2 of masofaniten + enzalutamide in mCRPC (2024) after a futility analysis on PSA90; the company later discontinued development (2025). The EXTRA-PC investigator trial in mHSPC closed early. AR-NTD inhibition remains unproven clinically despite compelling biology (AR-V7).
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Masofaniten" OR ABSTRACT:"Masofaniten" OR TITLE:"EPI-7386" OR ABSTRACT:"EPI-7386") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Masofaniten, not a curated reading list.
Pages like this
not linked directly; found by shared links- PersonEric J. Small
Shares Androgen receptor, Prostate cancer.
- InstitutionSidney Kimmel Comprehensive Cancer Center at Jefferson Health
Shares Androgen receptor, Prostate cancer.
- PathwayRNA splicing
Shares AR-V7 splice variant, Androgen receptor, Prostate cancer.
- PersonHoward I. Scher
Shares Androgen receptor, Prostate cancer.
- ProductBicalutamide
Shares Androgen receptor, Prostate cancer.
- ProductApalutamide
Shares Androgen receptor, Prostate cancer.
- PersonRahul Aggarwal
Shares Androgen receptor, Prostate cancer.
- ProductDegarelix
Shares Androgen receptor, Prostate cancer.